Patents by Inventor John J. Shay, Jr.

John J. Shay, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8633321
    Abstract: The present invention is an improved method for the preparation of (4-fluoro-3-pyridin-4-yl-benzyl)-carbamic acid tert-butyl ester, compound of formula I. The invention is directed to a method of synthesis for the compound of formula I in three steps, comprising formation of 5-((tert-butoxycarbonyl)aminomethyl)-2-fluorobenzeneboronic acid (compound 11), reaction of compound 11 under Suzuki coupling conditions to yield (4-fluoro-2-pyridin-4-yl-benzyl)-carbamic acid tert-butyl ester and selective hydrogenation of the aforementioned product under hydrogenation conditions yields compound I. The invention is also directed to the intermediates 5-((tert-butoxycarbonyl)amino-methyl)-2-fluorobenzeneboronic acid (compound 11), and (4-fluoro-3-pyridin-4-yl-benzyl)-carbamic acid tert-butyl ester (compound 13).
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: January 21, 2014
    Assignee: Sanofi-Aventis U.S. LLC
    Inventors: Nakyen Choy, John J. Shay, Jr., Adam W. Sledeski
  • Patent number: 8497379
    Abstract: The present invention is directed to a method for the preparation of 2,2,2-trifluoro-n-(4-fluoro-3-pyridin-4-yl-benzyl)-acetamide hydrochloride of the formula: and reaction intermediates used in the method.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: July 30, 2013
    Assignee: Sanofi
    Inventors: Yong Mi Choi-Sledeski, Nakyen Choy, Gregory B. Poli, John J. Shay, Jr., Patrick Wai-Kwok Shum, Adam W. Sledeski
  • Publication number: 20120283445
    Abstract: The present invention is directed to an indole benzylamine compound of formula I: useful as an inhibitor of tryptase. In addition, the present invention is directed to the use of the compound for treating a patient suffering from, or subject to, a physiological condition in need of amelioration by inhibition of tryptase, comprising administering to the patient of a therapeutically effective amount of the compound, and to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula I, and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: June 27, 2012
    Publication date: November 8, 2012
    Applicant: SANOFI
    Inventors: Yong Mi CHOI-SLEDESKI, Nakyen CHOY, Gregory Bernard POLI, John J. SHAY, JR., Patrick Wai-Kwok SHUM, Adam W. SLEDESKI
  • Publication number: 20120184745
    Abstract: The present invention is an improved method for the preparation of 4-fluoro-3-piperidin-4-yl-benzyl)-carbamic acid tert-butyl ester, compound of formula I. The invention is directed to a method of synthesis for the compound of formula I in three steps, comprising formation of 5-((tert-butoxycarbonyl)aminomethyl)-2-fluorobenzeneboronic acid (compound 11), reaction of compound 11 under Suzuki coupling conditions to yield (4-fluoro-2-pyridin-4-yl-benzyl)-carbamic acid tert-butyl ester and selective hydrogenation of the aforementioned product under hydrogenation conditions yields compound I. The invention is also directed to the intermediates 5-((tert-butoxycarbonyl)amino-methyl)-2-fluorobenzeneboronic acid (compound 11), and (4-fluoro-2-pyridin-4-yl-benzyl)-carbamic acid tert-butyl ester (compound 13).
    Type: Application
    Filed: March 22, 2012
    Publication date: July 19, 2012
    Applicant: SANOFI-AVENTIS U.S. LLC
    Inventors: Nakyen CHOY, John J. SHAY, JR., Adam W. SLEDESKI
  • Patent number: 8217178
    Abstract: The present invention is directed to an indole benzylamine compound of formula I: useful as an inhibitor of tryptase. In addition, the present invention is directed to the use of the compound for treating a patient suffering from, or subject to, a physiological condition in need of amelioration by inhibition of tryptase, comprising administering to the patient of a therapeutically effective amount of the compound, and to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula I, and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: February 16, 2011
    Date of Patent: July 10, 2012
    Assignee: Sanofi
    Inventors: Yong Mi Choi-Sledeski, Nakyen Choy, Gregory Bernard Poli, John J. Shay, Jr., Patrick Wai-Kwok Shum, Adam W. Sledeski
  • Publication number: 20110201647
    Abstract: The present invention is directed to an indole benzylamine compound of formula I: useful as an inhibitor of tryptase. In addition, the present invention is directed to the use of the compound for treating a patient suffering from, or subject to, a physiological condition in need of amelioration by inhibition of tryptase, comprising administering to the patient of a therapeutically effective amount of the compound, and to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula I, and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: February 16, 2011
    Publication date: August 18, 2011
    Inventors: Yong Mi CHOI-SLEDESKI, Nakyen CHOY, Gregory Bernard POLI, John J. SHAY, JR., Patrick Wai-Kwok SHUM, Adam W. SLEDESKI
  • Publication number: 20100174088
    Abstract: The present invention is an improved process for the preparation of a sodium/proton exchange inhibitor of sub-type 3 (NHE-3) useful in the treatment of sleep apnea and other related respiratory disorders.
    Type: Application
    Filed: December 14, 2009
    Publication date: July 8, 2010
    Applicant: SANOFI-AVENTIS U.S. LLC
    Inventors: Timothy Allen Ayers, Nakyen Choy, Harpal S. Gill, Andrea Hillegass, John J. Shay, JR., Volker Derdau